Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is:• The efficacy and safety of chidamide maintenance therapy in reducing the recurrence rate and GVHD incidence in high-risk AML patients after allo-HSCT.Participants will take oral chidamide (Epidaza) until 180 days after allo-HSCT.

Inclusion Criteria:Age ≥ 18 years old and ≤ 65 years old when signing the Informed Consent Form (ICF);KPS score > 60 or ECOG score 0-2;The expected survival period > 3 months;Received allo-HSCT and achieved complete remission (CR);Reach the standard of hematopoietic reconstitution (neutrophil count ≥ 0.5×10^9/L for 3 consecutive days without G-CSF application, platelet count ≥ 20×10^9/L for 7 consecutive days without platelet transfusion, Hb ≥ 80 g /L without red blood cell transfusion); and neutrophil count ≥ 1.5×10^9/L, platelet count ≥ 50×10^9/L within 45 days after transplantation;No central nervous system involvement or clinical symptoms after transplantation;Those who have no serious functional damage to important organs of the body;Fully understand and be informed of this study and sign the ICF; willing to follow and have the ability to complete all test procedures;Females of childbearing age must afford a serum pregnancy test within 7 days before the first dose, and the result should be negative; female participants and their partners should agree to use effective contraception from signing the ICF until 6 months after the last dose.Exclusion Criteria:Serious basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated hepatic insufficiency, renal function, gastrointestinal insufficiency, etc.;Uncontrolled active infection (including bacterial, fungal, or viral infection), and drug treatment is ineffective;Participating in other clinical studies, or planning to start treatment in this study and less than 4 weeks before the end of treatment in the previous clinical study;Poor graft function (PGF) occurred after allo-HSCT;Combined with other malignant tumors and require treatment;Active GVHD;Have a history of allergy to Chidamide;Pregnant or lactating females;Patients with known history of human immunodeficiency virus (HIV) virus infection and/or acquired immunodeficiency syndrome;Patients with active chronic hepatitis B or active hepatitis C;History of prolonged QT syndrome;Patients considered by other researchers to be unsuitable for this study.